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ABSTRACT
Epidemiological data indicate that patients who experience a traumatic brain injury (TBI)
have an elevated risk of developing a substance use disorder (SUD), but the underlying
neurobiological connections remain unclear. To further understand the relationship between TBI
and SUD, we investigated the effects of TBI on the abuse-related effects of oxycodone in
preclinical models. Our evaluation utilized a lateral fluid percussion injury of moderate severity in
adult male Sprague-Dawley rats. In the first aim, we tested the hypothesis that moderate TBI
increases the risk for relapse to an opioid use disorder as measured by reinstatement of leverpressing behavior following extinction in an intravenous oxycodone self-administration procedure.
In the second aim, we tested the hypothesis that moderate TBI increases physiological
dependence to oxycodone as measured by decreases in food-reinforced lever-pressing behavior
and increases in other withdrawal behaviors in both precipitated withdrawal and spontaneous
withdrawal. In tests for self-administration, brain-injured subjects, relative to non-injured subjects,
showed no significant differences in the number of oxycodone-reinforced sessions required to
meet stable maintenance criteria for lever-pressing behavior. Likewise, brain-injured subjects
showed no significant differences in the number of non-reinforced sessions to meet extinction
criteria for lever-pressing behavior relative to non-injured subjects. In tests for reinstatement, noninjured subjects reinstated responding under oxycodone-associated cue- and oxycodone primeinduced conditions, however, brain-injured subjects did not reinstate lever-pressing behavior
under any conditions. In tests for physical dependence, brain-injured subjects showed no
significant differences from non-injured subjects with regards to their mean withdrawal scores or
food-reinforced lever-pressing behavior. Overall, these data suggest that brain-injured patients
with no significant pre-morbid history of opioid abuse are at a lesser risk of relapse to opioid use
disorders. Moreover, the characteristic withdrawal syndrome in opioid-dependent patients may
not contribute to continued opioid abuse to a greater degree in brain-injured patients than
compared to non-injured patients.
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CHAPTER 1: INTRODUCTION
Substance abuse is a major public health concern that imposes a broad range of costs on
society.

The Diagnostic and Statistical Manual of Mental Disorders (DSM) characterizes

substance abuse as “a maladaptive pattern of substance use manifested by recurrent and
significant adverse consequences related to the repeated use of substances” [1]. In the earliest
human records, psychoactive substances were used by priests for religious ceremonies, healers
for medicinal purposes, and by the general population in a variety of ways [2]. Today, regular drug
use may evolve into a problem of drug abuse that taxes our healthcare system and results in lost
workplace productivity and accidental hazards. In 2004, the World Health Organization estimated
that at least 15.3 million people worldwide have drug use disorders and in 2007, the United States
National Drug Intelligence Center estimated that the total economic costs of substance abuse
exceeded 193 billion dollars annually [3,4]. In 2013, the National Survey on Drug Use and Health
estimated that 21.6 million Americans aged 12 or older abused illicit drugs in the past year based
on the DSM criteria for substance abuse [5]. A recent report by the National Institute of Health
Office of Budget indicated that the research awards supported by the National Institute on Drug
Abuse for the fiscal year of 2014 totaled nearly 770 million dollars [6]. Substance abuse and
dependence are well-recognized public health problems and remain of great interest to
researchers and research institutions alike.
Over the past century, substance abuse research has produced various therapeutics that
aid the cessation of substance abuse, but those treatments are not always efficacious and are
not without side-effects. Relapse to substance abuse remains a possibility even after successful
treatment or sustained abstinence. Withdrawal symptoms can persist at low intensities for days,
weeks, or months depending on the particular drug and doses at which the user became
dependent. In this case, resumption of substance abuse behaviors serves to alleviate the
persistent withdrawal dysphoria. In addition, limited periods of controlled, non-problematic drug
use can lead to rapid escalation in consumption after abstinence. In 2004, the National Survey on
5

Drug Use and Health reported that only 3.8 million Americans of the 22.5 million Americans that
were classified with substance dependence received treatment in that year [5]. Research in the
abuse of substances has yielded numerous advances in our understanding of relapse to
substance abuse, however, it remains a considerable public health issue that requires additional
research to adequately address.
Of interest to drug abuse researchers is the relationship between traumatic brain injury
(TBI) and substance use disorders (SUD). In 2006, the National Center for Injury Prevention and
Control estimated that 1.7 million people in the United States sustain a TBI each year, of which
275,000 are hospitalized and 1.365 million are released from an emergency department [7].
Similar estimates by the National Institutes of Health in 1998 indicated that 70,000 to 90,000
individuals that experience a TBI suffer from substantial long-term loss of physical, cognitive,
emotional, and behavioral function [8]. At present, the relationship between TBI and SUD has
been investigated almost entirely from the perspective of drug intoxication as the cause of trauma
[9]. It has been well-established that drug intoxication itself increases the risk of TBI and that the
chief causes of that trauma include motor vehicle accidents, falls, or involvement in acts of
violence [10,11].
Clinical evidence has emerged, however, of a correlation between the incidence of TBI
and SUD in patients that have no history of significant substance use prior to injury. In a 2000
study, it was reported that the relative risk of substance abuse in patients with TBI (22%) was 1.3
fold greater than the risk of substance abuse in patients without TBI (16.7%) [12]. In a 2004 study
of 188 TBI patients of whom 70 percent did not self-report substance abuse pre-injury, the
prevalence of substance abuse rose from 14 percent at 1-year post-injury to 17 percent 3-years
post-injury [13]. A 2004 study reported that TBI patients with no evidence of mental illness or
substance abuse-related service utilization in the year prior to injury had a 4.5 odds ratio of
substance abuse within the first year post-injury and still had a 1.4 times greater risk when
evaluated at 25-36 months post injury [14].
6

Overall, epidemiological data support a connection between experiencing a TBI and
developing a SUD. It is unclear, however, if the correlation between TBI and SUD reflects a coping
mechanism or if neuroanatomical and neurochemical changes induced by brain injury result in
increased vulnerability to development of substance use disorders. At the inception of this project,
the manifestation of SUD as a result of TBI had yet to be investigated in preclinical models [9].
Currently, there is only one published study on the effects of TBI in a preclinical model of selfadministration, more specifically a rodent model of ethanol self-administration where changes in
ethanol intake in ethanol experienced subjects were assessed before and after TBI

[15].

However, no research has been published regarding the TBI-induced changes in intake of any
other abused substance in drug naïve or drug experienced subjects.
Since bodily trauma is often comorbid with TBI, clinical management of pain with opioid
analgesics is common in TBI patients. It follows, then, that TBI patients are likely to be exposed
to opioid analgesics during the course of their medical care. Over the last decade, as prescription
opioid sales sharply increased, rates of prescription opioid abuse have also continued to rise, and
as a result treatment admissions and deaths due to overdose are at epidemic levels [16,17].
Mortality rates due to opioid-analgesic poisonings nearly quadrupled in the years between 1999
and 2011, and in 2011 alone there were 41,340 deaths due to drug poisoning, 41% (16,917
deaths) of them involved opioid analgesics [18]. In cases of prescription opioid abuse that do not
result in death, continued abuse of medication is common. In cases of prescription opioid abuse
where abstinence is an outcome, relapse remains a possibility [19]. Moreover, repeated use of
pain medication is likely to lead to the development of physical dependence [20] and withdrawalinduced dysphoria after abrupt cessation of opioid intake may contribute to continued drug taking
[21].
Given the greater incidence of substance abuse in brain-injured patients and high
probability of exposure to opioids prescribed in the course of treatment following brain injury, we
investigated the effects of TBI on the response to oxycodone in preclinical models of abuse7

related behaviors in rats. In the first aim, we tested the hypothesis that moderate TBI increases
the risk for relapse to an opioid use disorder as measured by reinstatement of lever-pressing
behavior following extinction in an intravenous oxycodone self-administration procedure. In the
second aim, we tested the hypothesis that moderate TBI increases physiological dependence to
oxycodone as measured by decreases in food-reinforced lever-pressing behavior and increases
in other withdrawal behaviors in both precipitated withdrawal and spontaneous withdrawal.
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CHAPTER 2: PART 1
2.1 OVERVIEW OF CLASSICAL CONDITIONING
In 1927, Ivan Pavlov published a report titled Conditioned Reflexes, An Investigation of
the Physiological Activity of the Cerebral Cortex. Pavlov systematically investigated the
adjustments organisms make in response to the presentation of various environmental and
proprioceptive stimuli [22]. In a typical Pavlovian experiment, a neutral stimulus (NS), which
initially elicits no physiological response, is repeatedly paired with the presentation of an
unconditional stimulus (US), a stimulus that alone is capable of eliciting a physiological response
termed the unconditioned response (UR). Organisms learn to associate the NS with the US, and
after several couplings, the NS alone can trigger a response that is similar to the response
triggered by the US, known as the conditioned response (CR). At this point, the NS is no longer
neutral since it has gained the ability to elicit a physiological response and is now referred to as
the conditional stimulus (CS). In Pavlov’s experiments, dogs were conditioned to salivate (CR)
upon presentation of a tone (CS) after repeated pairing with food powder (US). In the case of
drug-related behaviors, a NS is predictably followed by a US, the effects of the drug. As a result
of repeated pairings, the CS elicits a CR which is similar to that of the UR, or the drug effects.
Conditioned cues that are present during drug administration serve as conditioned reinforcers of
drug-seeking behaviors if the effects of the drug are positively reinforcing [23].
In 1935, Clark Hull expanded on the understanding of Pavlov’s experiments by introducing
the drive reduction theory. Motivation, Hull proposed, has both drive and incentive components.
He states, “the incentive is that substance or commodity in the environment which satisfies a
need, i.e., which reduces a drive” [24]. In 1948, Abraham Wikler applied Hull’s theory to the
phenomenon of substance abuse relapse. He proposed that through a process of associative
learning, neutral stimuli in the environment can, over the course of many pairings with drug taking,
come to elicit conditioned withdrawal responses in drug dependent subjects [25]. For example, if
the sight of a needle, syringe, or white powder (NS) is repeatedly paired with a diminishing drug
9

level (UR) during withdrawal (US), those cues may then serve as conditional stimuli (CS), which
elicit a conditioned withdrawal response (CR). If the conditioned cues are presented after a period
of abstinence from substance abuse, the subject’s desire to relieve the conditioned dysphoria
may result in a relapse to drug consumption [26,27]
2.2 OVERVIEW OF OPERANT CONDITIONING
Over the last several decades, animal models have been used extensively to investigate
the neurobiological and behavioral mechanisms underlying vulnerability to relapse. A
“reinstatement model” allows researchers to analyze drug-seeking and relapse-like behavior.
Many experimental models in substance abuse research, including the reinstatement model as it
is used in self-administration, are fundamentally dependent on the principles of operant
conditioning. In 1930, Burrhus Skinner first described the use of operant chambers to study animal
behavior in a paper titled On the Conditions of Elicitation of Certain Eating Reflexes [28–30]. In
1938, Skinner published The Behavior of Organisms which set forth the principles for the
experimental analyses that we perform today. In a typical Skinnerian experiment, organisms
adjust their behavior according to the behavior-consequence contingencies specified by the
investigators. If a consequence increases the probability of the behavior antecedent to it, it is
termed a reinforcer. If a consequence decreases the probability of a behavior antecedent to it, it
is termed a punisher. If a reinforcing or punishing stimulus is presented it is termed positive,
however, if it is removed from the system it is termed negative. The relationship between the
behaviors and their consequences is referred to as a two-term contingency. If for any two-term
contingency, the probability of emission of the behavior is increased or decreased only in the
presence of a given stimulus, it is known as a three-term contingency and the modulating stimulus
is known as discriminative stimulus [31]. For example, a light in an illuminated state may signal
that the emission of a lever press behavior will consequently be followed by the presentation of a
food pellet, however, when the light is not illuminated the contingency does not apply. In this
regard, the illuminated light serves as the discriminative stimulus and the presentation of the food
10

pellet is a form of positive reinforcement since the stimulus is added to the system and increases
the probability of the behavior antecedent to it. In these experiments, the effect of a specified
consequence on a particular behavior can be evaluated by measuring the total number of emitted
behaviors or the rate of the emission of those behaviors.
It is also possible to manipulate the way a reinforcer is delivered as a function of
responding to investigate the ways in which organisms adjust to consequences of their behaviors.
In operant conditioning, reinforcement schedules commonly consist of ratio schedules and
interval schedules. In ratio schedules, a specified number of behaviors must be emitted for the
delivery of reinforcement. For example, in a fixed ratio schedule (FR) the number of required
responses is fixed whereas in a variable ratio schedule (VR), the number of required responses
varies around a mean of the ratio of the schedule. In interval schedules, a specified amount of
time must elapse after the last reinforced behavior before subsequent behaviors are reinforced.
For example, in a fixed interval schedule (FI) the amount of time that must elapse is fixed whereas
in a variable interval schedule (VR) the amount of time that must elapse varies around a mean of
the interval of the schedule [32]. Schedules of reinforcement are frequently manipulated in the
case of self-administration procedures and reinstatement procedures as discussed in the
subsequent sections.
2.3 ORIGINS OF THE SELF-ADMINISTRATION PROCEDURE
In 1940, Sidney Spragg published a monograph titled Morphine Addiction in
Chimpanzees. Spragg applied Hull’s drive reduction theory to chimpanzees. In an experimental
room separate from their living quarters, chimpanzees were administered morphine injections
twice daily for an average four weeks or until they were opioid-dependent. Given a choice between
food and drug, chimpanzees preferred the injection to food when experiencing withdrawal
symptoms. Spragg’s results suggest that relief of morphine-induced withdrawal symptoms may
serve as sufficient reinforcement for the development of drug-seeking behavior and that the
positive drug effects serve as conditioned reinforcers as later suggested by Wikler [25,33].
11

In 1957, Horace Beach published a report titled Morphine Addiction in Rats in which he
used a Y-choice discrimination box to determine whether rats would seek stimuli associated with
the drugs effects [34]. After habituation to the apparatus, subjects were given the choice of two
distinctly different contexts with unique cues (goal boxes). After baseline preference
determination, rats were administered morphine or saline injections once daily for twelve days
and then immediately placed in either their preferred or non-preferred goal box. Given a choice
between stimuli previously associated with the drug effects and stimuli not previously associated
with the drug effects, rats showed a significant preference for the stimuli previously associated
with drug effects as compared to their baseline preference.

As suggested by Spragg in 1940

and Wikler in 1948, Beach’s results support the hypothesis that both the euphoric effects of
morphine and the action of morphine in relieving withdrawal distress are sufficiently reinforcing to
promote the development of morphine-seeking behavior.
In 1962, James Weeks published a paper in Science titled Experimental Morphine
Addiction: Method for Automatic Intravenous Injections in Unrestrained Rats, which laid the
foundation for the self-administration procedures that are widely used in substance abuse
research today. Weeks surgically implanted polyethylene cannulae into the jugular veins of albino
female rats using a technique developed by Vojin Popovic [35]. With the ability to directly introduce
morphine sulfate to the rodent circulatory system, Weeks applied Skinner’s (1938) fundamental
principles of operant conditioning to study the effect of drugs on animal behavior. In operant
boxes, relatively unrestrained rodents could then utilize a self-injection technique to intravenously
administer morphine sulfate by lever press activation of an automatic syringe driver. It was shown
that the rate of self-administration of morphine varied inversely by the dose. It was also shown
that morphine acted as a reinforcer that produced almost immediate relief from withdrawal in
dependent subjects as shown previously by Spragg (1940) in chimpanzees and Beach (1957) in
rats [36].
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2.4 ORIGINS OF THE REINSTATEMENT PARADIGM
Substance abuse relapse is studied in animal models of reinstatement which often utilize
self-administration procedures. In a typical self-administration experiment with a reinstatement
design, subjects learn to press a lever in an operant chamber for an intravenous infusion of drug
during the acquisition phase. Once the subjects reliably press a lever for drug infusion, and stable
drug-taking behavior is reproducible, the subjects are considered to be in the maintenance phase.
It is then possible to extinguish the learned contingency by replacing the drug infusion with a
saline infusion or no infusion, of which the latter two do not serve as reinforcing stimuli when
presented. Often this results in an extinction burst which is characterized by a sudden and
temporary increase in the subject’s response frequency.

Once subjects learn that the

reinforcement is no longer a consequence of lever-pressing behavior, they are considered to be
in the extinction phase. A non-contingent, pre-session drug injection, referred to as a drug priming,
may renew the previously extinguished expression of lever-pressing behavior, even when the
emission of that behavior does not result in drug infusion. A drug priming model is designed to
simulate an exposure to the drug that was abused or a related drug after treatment or abstinence
in humans. Similarly, an exteroceptive cue, or cue priming and a noxious stimulus or stress
priming will also result in the renewed expression of previously extinguished lever pressing
behavior. A cue priming model is designed to simulate exposure to drug-associated cues, such
as drug paraphernalia, that can lead to renewed drug taking. A stress priming model is designed
to simulate renewed drug taking in response to major life stressors such as grief, sorrow, and
anger.
In 1971, Rodger Stretch, Gary Gerber, and Susan Wood published a study titled Factors
Affecting Behavior Maintained by Response-Contingent Intravenous Infusions in Squirrel
Monkeys which utilized such a procedure. In daily two hour sessions, subjects developed drugseeking behavior for intravenous infusions of d-amphetamine on a modified progressive ratio
schedule of reinforcement. Responding was then extinguished by replacing infusions of d13

amphetamine with infusions of saline. When pre-session intramuscular injections of damphetamine were administered, responding was restored and indistinguishable from that
observed when drug infusions were available [37]. Researchers later termed this phenomenon
prime-induced reinstatement.
In 1976, Marvin Davis and Stanley Smith, using a self-administration procedure, explored
the motivational properties of secondary reinforcers derived from the primary reinforcing effects
of intravenous morphine injections. Subjects were trained to acquire morphine self-administration
with a buzzer presentation during each morphine infusion. By substituting saline for morphine,
the lever press behavior was extinguished in the absence of the buzzer, the reinforcing
conditioned stimulus. In subsequent sessions, elevated responding occurred during the
presentation of the buzzer, confirming the occurrence of secondary reinforcement [38].
Researchers later termed this phenomenon cue-induced reinstatement.
In 1995, Yavin Shaham and Jane Stewart tested the effect of footshock stress on relapse
to heroin-seeking behavior. Subjects trained on intravenous heroin self-administration were
exposed to footshock stress in a reinstatement procedure after extinction. After numerous
extinction sessions, and after a prolonged drug-free period, the footshock stress produced
responding that mimicked the effect of a non-contingent priming infusion of heroin. Such results
suggest that stress is a powerful stimulus for relapse to drug-seeking behavior and is comparable
to heroin itself [39]. Researchers later termed this phenomenon stress-induced reinstatement.
In summary, these three approaches are commonly utilized to reinstate drug-taking
behavior in preclinical models. A non-contingent, pre-session drug injection, referred to as a drugpriming; presentation of an exteroceptive cue, or cue priming and a noxious stimulus or stress
priming have all been repeatedly demonstrated to renew expression of extinguished lever
pressing behavior even when the emission of that behavior does not result in drug infusion.
Overall, the individual approaches to inducing reinstatement in preclinical models have provided
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information about the underlying neuroanatomical circuitry and neurochemical mechanisms that
drive relapse in humans.
2.5 CURRENT UNDERSTANDING OF REINSTATEMENT TO OPIOID SELFADMINISTRATION
A database search for published literature on reinstatement of opioid self-administration
yields a number of preclinical studies in which agonists and antagonists are screened as potential
pharmacotherapies for relapse prevention. Such approaches are used to elucidate the
neurobiological and neurochemical mechanisms that mediate relapse. Our test drug of abuse,
oxycodone, has been used in only a limited capacity in preclinical studies on reinstatement of selfadministration, compared to other opioids such as heroin and morphine.
In a 2005 study, investigators tested the hypothesis that co-administration of ultra-lowdoses of naltrexone, a mu-opioid antagonist, with oxycodone, a mu-opioid agonist, attenuate
prime-, cue-, and stress-induced reinstatement [40]. Male Sprague-Dawley rats individually
housed under a reverse light-dark cycle with ad libitum access to food and water, acquired
oxycodone-reinforced self-administration behavior in combination with naltrexone (1, 10, 100
pcg/kg/infusion) in 10 daily, three-hour sessions under an FR10 schedule of reinforcement.
Subjects’ active lever-pressing behavior during acquisition and maintenance sessions resulted in
an infusion of oxycodone infused over 10 seconds and a 30-second presentation of the light cue.
Subjects’ active lever-pressing behavior during extinction sessions had no programmed
consequences.
In cue- and prime-reinstatement sessions (0.25 mg/kg, SC), subjects that previously selfadministered ultra-low doses of naltrexone (1, 10 pcg/kg/infusion) in combination with oxycodone
showed attenuated levels of responding. In stress-induced reinstatement sessions, subjects that
previously self-administered naltrexone in combination with oxycodone showed a naltrexone
dose-dependent attenuation in responding. Such a result is a successful demonstration of the
ability to alter reinstatement of lever-pressing behavior following extinction by manipulation of
15

opioid neurotransmission. It is suggested, then, that patients initially acquiring a drug taking
behavior with oxycodone and naltrexone in combination may be less liable to abuse opioids after
treatment or abstinence from drug taking.
In 2014 study, investigators tested the hypothesis that ATPM-ET, a kappa-opioid agonist
with mixed mu-opioid agonist-antagonist activity, attenuates prime-induced reinstatement in
subjects receiving opioids [41]. Male Sprague-Dawley rats individually housed on a reverse lightdark cycle acquired heroin-reinforced nose-poking behavior under a FR2 schedule of
reinforcement (50 mcg/kg/infusion) in three-hour operant sessions, limited to 25 injections per
session, for 10 consecutive days. In the acquisition phase, subjects were administered saline or
ATPM-ET (1.2 or 2.4 mg/kg, IP) 15 minutes prior to session and subjects continued responding
for 8 to 10 days until subjects could discriminate between the active and inactive hole for 3
consecutive days. Subjects extinguished responding in daily three-hour extinction sessions for 3
weeks where heroin solution was replaced with saline solution. In reinstatement tests, ATPM-ET
(1.2 and 2.4 mg/kg, IP) or saline (1 ml/kg, IP) was injected 15 minutes prior to injection of heroin
(0.25 mg/kg, SC) or saline (1 ml/kg, SC), which was injected 10 minutes prior to subject placement
in chamber. It is reported that ATPM-ET at high doses attenuated the ability of heroin to reinstate
active nose-poking behavior without affecting inactive nose-poking responding. It is suggested,
then, that ATPM-ET may prevent heroin priming induced reinstatement of extinguished drug
seeking behavior.
In a 1996 study, investigators tested the hypothesis that dopamine antagonists attenuate
prime- and stress-induced reinstatement in subjects receiving opioids [42]. Male Long-Evans rats
housed on a reverse light-dark cycle, acquired heroin-reinforced lever-pressing behavior under a
FR1 schedule of reinforcement (25 mcg/kg/infusion) in four, three-hour operant sessions per day,
two sessions per light cycle, for eight to eleven consecutive days. In the extinction phase, subjects
received an infusion of saline for pressing the previously reinforced lever for five consecutive
days. Subsequently, subjects were tested twice, separated by 48 hours, for reinstatement of self16

administration of heroin under either prime or stress conditions in three-hour sessions where
either non-contingent, subcutaneous heroin injection (0.25 mg/kg, 10-minute incubation) or
intermittent footshock (0.5 mA, 0.5 s active, 10-70 s inactive, 10-minute session) were given prior
to session. As in the extinction phase, subjects received a saline infusion under reinstatement
conditions for pressing the previously active lever. Subjects were pretreated with either saline,
the opioid antagonist, naltrexone (1 or 10 mg/kg, SC), the D1-like receptor antagonist SCH 23390
(0.05 or 0.1 mg/kg, IP), the D2-like receptor antagonist raclopride (0.25 or 0.5 mg/kg, IP), or the
non-selective DA antagonist flupenthixol (3 or 6 mg/kg, IM). In stress conditions, only flupenthixol
dose-dependently attenuated reinstatement. In prime conditions, however, naltrexone, raclopride,
and flupenthixol dose-dependently attenuated reinstatement.
It is possible to conclude, then, that dopaminergic signaling plays an important role in
reinstatement of behavior following exposure to aversive stimuli, or re-exposure to heroin, since
flupenthixol, the non-selective dopaminergic antagonist attenuated both stress-induced and
prime-induced reinstatement in this procedure. However, these findings also suggest that stressinduced reinstatement and prime-induced reinstatement are also mediated by at least two
different neurobiological or neurochemical systems since naltrexone and raclopride, which have
different mechanisms of action than flupenthixol, attenuated prime-induced reinstatement, but not
stress-induced reinstatement.
In a 2012 study, investigators tested the hypothesis that dopamine antagonists attenuate
prime-induced reinstatement in subjects receiving opioids [43]. Food-restricted (20 g daily), male
Sprague-Dawley rats housed on a reverse light-dark cycle acquired heroin-reinforced nosepoking behavior under a FR1 schedule of reinforcement (30 mcg/kg/infusion) in daily three-hour
operant sessions for 12 to 14 days. In the extinction phase, subjects received an infusion of saline
for nose-poking the previously reinforced hole. Subsequently, subjects were tested for primeinduced reinstatement in two-hour sessions, where a non-contingent, subcutaneous heroin
injection (0.25 mg/kg) was administered prior to session. In reinstatement sessions, prior to prime
17

injection, subjects were treated with saline or levotetrahydropalmatine (1.25, 2.5, or 5 mg/kg, IP),
a D1/D2/D3 antagonist. In prime conditions, levotetrahydropalmatine dose-dependently
attenuated heroin prime-induced reinstatement—that is, that the number of nose-pokes in the
active hole was significantly decreasing as a function of increasing treatment dose.
It is common, in reinstatement studies, to include complementary data such as foodreinforced lever press performance or locomotion data that indicate that a particular treatment
produces a specific effect, or one that selectively modulates a single system or set of systems,
and not a non-specific effect, that non-selectively modulates many or all systems. In this study,
investigators elected to include nose-poke performance data on the non-reinforcing, or inactive
nose-poke hole. These data suggest that the treatment mechanism is specific to a single system
or a set of systems, such as the mesocorticolimbic dopamine system, which mediates behavior
in accordance with a multiple-term contingency. Furthermore, data from locomotion assays
indicate that only high doses of levotetrahydropalmatine (5 mg/kg, IP) significantly decrease
locomotion, which reinforces the notion that the treatment acts directly and not through sedative
effect. It is possible to conclude, then, that levotetrahydropalmatine may have therapeutic utility
in the prevention of relapse prompted by re-exposure to drug.
In a 2013 study, investigators tested the hypothesis that dopamine antagonists attenuate
prime- and cue-induced reinstatement in subjects receiving opioids [44]. Male Sprague-Dawley
rats individually housed on a reverse light-dark cycle acquired heroin-reinforced nose-poking
behavior under a FR1 schedule of reinforcement (50 mcg/kg/infusion) in daily four-hour operant
sessions for 14 days. In extinction sessions, there were no programmed consequences for
behavior in daily one-hour sessions for 10 consecutive days. Subsequently, subjects were tested
for reinstatement of self-administration of heroin under cue conditions and prime conditions in
two-hour sessions. In cue conditions, visual and auditory cues were presented for five seconds
at the start of the session and for each nose-poke on the previously reinforced hole thereafter.
However, no reinforcement was delivered for behavior. In prime conditions, subjects were
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administered heroin (0.1 or 0.25 mg/kg, SC) 10 minutes prior to sessions in which no
reinforcement was delivered for behavior. In cue conditions, risperidone (0.01, 0.03, or 0.1 mg/kg,
IP), a D2/D3/D4 antagonist, was administered 10 minutes prior to session, and in prime
conditions, 10 minutes prior to prime injection.
In cue conditions, risperidone (0.03 and 0.1 mg/kg, IP) pre-treatment dose-dependently
attenuated reinstatement of nose-poking behavior on the active hole with no significant change
in nose-poking behavior on the inactive hole. In heroin (0.1 or 0.25 mg/kg, SC) prime conditions,
risperidone (0.01, 0.03, or 0.1 mg/kg, IP) pre-treatment had no significant effect on reinstatement
of nose-poking behavior on either the active or inactive hole. Lai et al, suggest that while
risperidone serves as an antagonist for numerous DA receptor subtypes, most notably D2
receptors, they also report that risperidone has a greater affinity for 5HT-2A receptors exerts
similar action at adrenergic receptors and histamine receptors. It is possible to suggest, then, that
risperidone, and drugs with similar mechanism of action, may have therapeutic utility in the
prevention of relapse prompted by cues previously associated with drug-taking behavior.
In a 2014 study, investigators tested the hypothesis that the mixed dopamine agonistantagonist, L-stepholidine, attenuates cue-induced reinstatement in subjects receiving an opioid
agonist [45]. Male Sprague-Dawley rats housed on a reverse light-dark cycle acquired heroinreinforced nose-poking behavior under a FR1 schedule of reinforcement (30 mcg/kg/infusion) in
daily two-hour operant sessions. In the acquisition phase, each infusion was paired with a 5
second presentation of visual (light) and auditory (tone) cue. In the extinction phase, subjects’
responding had no programmed consequences for behavior. Subsequently, subjects were tested
for cue-induced reinstatement in two-hour operant sessions. In the reinstatement test sessions,
subjects were pre-treated with saline or L-stepholidine (2.5, 5.0, 10.0 or mg/kg, IP) 30 minutes
prior to session. In these sessions nose poking behavior was not reinforced with heroin. It is
reported that L-stepholidine, but not saline, significantly and dose-dependently attenuates cue-
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induced reinstatement. Furthermore, L-stepholidine and saline had no significant effect on
locomotor activity nor nose-poking behavior on the inactive hole.
In a concurrent 2014 study, performed by the same group, investigators tested the
hypothesis that the same mixed dopamine agonist-antagonist, L-stepoholidine, attenuates cueinduced reinstatement in subjects receiving an opioid agonist [46]. Male Sprague-Dawley rats
individually housed under a reverse light-dark cycle acquired heroin-reinforced nose-poking
behavior under a FR1 schedule of reinforcement (50 mcg/kg/infusion) in daily three-hour operant
sessions for 12 consecutive days. In the extinction phase, there were no programmed
consequences for behavior in daily two-hour sessions for 12 consecutive days. Subsequently,
subjects were tested for heroin prime-induced reinstatement (0.25 mg/kg, SC). In the
reinstatement procedure, subjects pre-treated with saline or L-stepholidine (2.5, 5.0 or 10.0
mg/kg, SC) 30 minutes prior to session. It is reported that L-stepholidine, but not saline,
significantly and dose-dependently attenuated heroin prime-induced reinstatement. Furthermore,
L-stepholidine and saline had no significant effect on locomotor activity nor inactive nose-poking
behavior on the inactive hole.
Indeed, L-stepholidine is characterized as a dual D1-receptor agonist and D2-receptor
antagonist [47–50] and therefore supports the rationale for use of dopamine agonist-antagonist
approaches to relapse control following opioid abuse. Since the dopamine receptor and its
subtypes have been major targets of investigation in the relapse to opioid abuse, the use of Lstepholidine is justified, even with mixed action at dopamine receptors. However, others also
report significant partial agonistic activity at 5-HT1A receptors [51]. It is possible to conclude then,
that, while L-stepholidine may decrease relapse liability, it may not mediate these effects through
dopamine receptors alone. Overall, these pharmacological manipulations provide insight into the
receptor mechanisms which mediate relapse to opioids, induced by both re-exposure to drugassociated cues and renewed drug taking. Collectively, these studies demonstrate that the
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mesocorticolimbic dopamine system is involved in the mediation of prime-, cue-, and stressinduced reinstatement of heroin-reinforced self-administration behavior.
It should be noted that while the authors of each study characterize their experiments with
a great degree of detail, no single study reported a complete set of controlled variables, which are
necessary to make direct comparisons. For example, some studies explicitly state their acquisition
and extinction criteria, while other studies differ in that they report only the number of operant
sessions or the number of days required to meet an unspecified set of criteria. Furthermore, no
two studies used exactly the same values in their set of controlled variables. Even experiments
reported by the same group—seeking to answer nearly identical questions—in two separate
publications in the same year, had marked variations in their procedures, including the drug
infusion concentration. In addition, while most of the studied pre-treatment ligands are selective
for a particular receptor or receptor subtype, these ligands tend to bind, to at least some degree,
many different molecular targets. It should be noted, then, that the effects observed in the
reviewed reinstatement assays may be due to a combination of ligand-receptor interactions, and
not solely due to the interaction between the receptor and ligand with greatest affinity.
In summary, many of these studies have demonstrated that receptors in the
mesocorticolimbic dopamine system play a role in the modulation of effects of acute opioid
exposure, opioid-associated cues, and stressors on the reinstatement of opioid seeking. Overall,
the reinstatement paradigm has been shown to be a viable platform for the investigation of
relapse-like behavior and the variables which may impact relapse including pharmacological,
genetic and environmental variables. Our study utilized this well-established model to investigate
the hypothesis that moderate TBI increases the risk for developing an opioid use disorder as
measured by reinstatement of lever-pressing behavior previously reinforced by oxycodone in a
self-administration procedure, a proposed model of preoccupation and anticipation leading to
relapse.
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CHAPTER 2: PART 2
2.6 CURRENT UNDERSTANDING OF PHYSICAL DEPENDENCE TO OPIOIDS
In the development of drug addiction, drug taking often begins in a social setting and is
compounded by acute reinforcement. Escalation of drug taking can lead to a transition from
compulsive use to physical dependence and withdrawal symptoms following abstinence. It is
proposed that dysphoria, a result of cessation of drug use in dependent individuals, may be a
sufficient motivating factor in the reinitiation of drug taking, also known as relapse. According to
Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, physical dependence refers
to an “altered physiological state produced by the repeated administration of drug, which
necessitates the continued administration of the drug to prevent the appearance of a stereotypical
syndrome, the withdrawal or abstinence syndrome, characteristic for a particular drug” [52]. The
development of physical dependence is not predicated on the motivating factors for drug taking
such as misuse, abuse, and supervised medical use, rather it is the repeated drug administration
alone that results in altered physiology [53,54].
It is proposed that while these reinforcing effects serve to promote the initial development
of drug taking through positive reinforcement, physical dependence is important in the
continuation and maintenance of drug taking which serve to alleviate an aversive withdrawal
syndrome, a form of negative reinforcement [55–59]. It follows then, that a withdrawal syndrome,
as occurs with opioids, can be a major determinant of continued use and abuse of a drug [60]. In
both preclinical and clinical studies, withdrawal will occur after abrupt cessation of chronic opioid
intake, or spontaneous withdrawal [61], and through the administration of an opioid antagonist, or
precipitated withdrawal [62]. Our study used this well-established approach to test the hypothesis
that moderate TBI increases the risk for developing a physiological dependence to oxycodone as
measured by changes in food-reinforced lever-pressing and other withdrawal behaviors during
both precipitated and spontaneous withdrawal.
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It is reported that a strong correlation exists between the species specific withdrawal signs
and symptoms of both humans and rodents with respect to physical dependence induced by
repeated administration of opioids [63–66]. In humans, signs and symptoms of withdrawal include
dysphoric mood, nausea or vomiting, muscle aches, cramps, lacrimation, rhinorrhea, pupillary
dilation, piloerection, sweating, chills, diarrhea, yawning, fever, insomnia, craving for opioid drug,
sneezing, tachycardia, and hypertension (see table for qualifying criteria) [67–70]. In rodents,
signs and symptoms of withdrawal include diarrhea, rhinorrhea, piloerection, teeth chattering, “wet
dog shakes,” genital grooming and penile erection and decreased food consumption (anorexia)
[71].
Operant responding has been shown as a sensitive measure in the detection of withdrawal
signs and symptoms. For example, in a model of physical dependence, food-reinforced operant
responding is disrupted in a precipitated withdrawal procedure by the administration of an opioid
antagonist in opioid-dependent subjects [72,73]. Moreover, doses of an opioid antagonist that are
sufficiently small to not result in observable withdrawal in morphine-dependent rats will disrupt
food-reinforced responding [74]. Collectively, these studies suggest that the development of
physical dependence as an adaptive, homeostatic response to the acute and chronic
administration of opioids is well established in rodent models and can be quantified through gross
observation of unlearned behavior and learned behavior as in schedule controlled responding
[72,74,75].
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Qualification Criteria for Withdrawal Syndrome
[DSM 5] Opioid Withdrawal Diagnostic [ICD-10]2 Opioid Withdrawal State
Criteria 292.0 (F11.23)
Criteria (F11.3)
A. Presence of either of the following:
A. The general criteria for withdrawal state
1. Cessation of (or reduction in) opioid use
(F1x.3) must be met. (Note that an
that has been heavy and prolonged (i.e.,
opioid withdrawal state may also be
several weeks or longer).
induced by administration of an opioid
2. Administration of an opioid antagonist
antagonist after a brief period of opioid
after a period of opioid use.
use.)
B. Three (or more) of the following developing
B. F1x.3 Withdrawal State Criteria:
within minutes to several days after
1. There must be clear evidence of
Criterion A:
recent cessation or reduction of
1. Dysphoric mood
substance use
2. Nausea or vomiting
after repeated, and usually prolonged
3. Muscle Aches
and/or high-dose, use of that
4. Lacrimation or rhinorrhea
substance.
5. Pupillary dilation, piloerection, or
2. Symptoms and signs are compatible
sweating
with the known features of a withdrawal
6. Diarrhea
state from the particular substance or
7. Yawning
substances (see below).
8. Fever
3. Symptoms and signs are not
9. Insomnia
accounted for by a medical disorder
C. The signs or symptoms in Criterion B cause
unrelated to
clinically significant distress or impairment in
substance use, and not better
social, occupational, or other important
accounted for by another mental or
areas of functioning
behavioral disorder.
D. The signs or symptoms are not attributable
C. Any three of the following signs must
to another medical condition and are not
be present:
better explained by another mental disorder,
1. Craving for an opioid drug
including intoxication or withdrawal from
2. Rhinorrhoea or sneezing
another substance
3. Lacrimation
4. Muscle aches or cramps
5. Abdominal cramps
6. Nausea or vomiting;
7. Diarrhea
8. Pupillary dilatation
9. Piloerection, or recurrent chills
10. Tachycardia or hypertension
11. Yawning
12. Restless sleep
1

[1] American Psychiatric Association., (2013). Diagnostic and Statistical Manual of Mental
Disorders, 5th Edition (DSM-5).
[2] World Health Organization., (2010). International Classification of Diseases (ICD).
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CHAPTER 3: MATERIALS AND METHODS
3.1 SUBJECTS
Subjects were adult male Sprague-Dawley rats individually housed under a reverse lightdark cycle (light 1800 to 0600; dark 0600 to 1800) with ad libitum access to food and water in a
vivarium approved by the Association for Assessment and Accreditation of Laboratory Animal
Care (AAALAC). All procedures were reviewed and approved by the Virginia Commonwealth
University (VCU) Institutional Animal Care and Use Committee (IACUC) and the Animal Care and
Use Review Office (ACURO) of the United States Army Medical Research and Materiel Command
(USAMRMC) Office of Research Protections (ORP).
3.2 FLUID PERCUSSION INJURY PROCEDURE
Subjects underwent a fluid percussion procedure to induce moderate, closed-head,
intracranial injury (Day 0) following handling, operant training, and when appropriate intravenous
catheterization for subsequent behavioral procedures. Subjects were anesthetized with 3 percent
isoflurane vapor and transferred to a stereotaxic device for craniectomy and maintained on 4
percent isoflurane for the duration of the procedure. Subjects were divided approximately evenly
into two groups: 1) a control group that underwent all procedures with the exception of the fluid
percussion injury (referred to as control, non-injured, or sham subjects) and 2) a treatment group
that underwent all procedures including the fluid percussion injury (referred to as injured, braininjured, or TBI subjects).
One longitudinal incision of 9 mm in length was made in the scalp and the underlying
fascia was displaced to expose the dorsal surface of the exterior skull. A craneictomy of 4.8 mm
in diameter was then performed by hand with a trephine over the right motor cortex at the midpoint
between bregma and lambda and the central fissure and lateral ridge. A cannula fabricated from
the hub of a female leur-lock compatible 20-gauge needle was affixed to the skull at the
craniectomy site and secured to the skull with dental acrylic. Once the dental acrylic hardened,
the cannula was filled with sterile saline and the intracranial injury was induced with a fluid
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percussion device (Custom Design and Fabrication, VCU, Richmond, VA). Subsequently, a visual
observation to confirm the integrity of the dura mater was performed. A piezoelectric sensor in
the fluid percussion device measured the profile of the pressure pulse and an oscilloscope
recorded and reported the resultant amplitude and duration of the pressure pulse.
Subjects’ transient loss of consciousness was assessed immediately after the procedure
by measurement of the righting reflex assessed by the time each subject required to reorient itself
to the prone position when placed in the on its back. It reported by numerous sources that the
time to return of the righting reflex, is a valid measure of the extent and severity of tissue damage
[76–82]. After these procedures, the scalp was closed with a polydioxanone suture and the
subject was returned to a clean, warmed, home chamber for recovery.
Statistical analysis of the recorded time to return of righting reflex between the braininjured and non-injured subjects was performed using both a Student’s T-Test and a Levene’s
Test for Equality of Variances. Subjects whose recorded time to return to right reflex was greater
than two standard deviations from the mean did not qualify for inclusion in experiments and were
excluded from calculations in the final data analysis.
3.3 CATHETERIZATION PROCEDURE
Subjects for testing in the self-administration procedure underwent surgical implantation
of an indwelling, polyurethane catheter five days prior (Day -5) to the fluid percussion procedure
(Day 0). Subjects were pre-medicated with 2 mg/kg morphine and anesthetized with 4 percent
isoflurane vapor and maintained for the duration of the procedure. One longitudinal incision of
approximately 20 mm in length was made in the skin on the ventral surface of the neck, right
lateral and parallel to the trachea in line with the point of the mandible. A blunt dissection
technique was performed to locate and isolate a 10 mm segment of the right external jugular vein.
Once the vein was located and isolated, the cranial end of the segment was ligated with a braided
nylon suture. Subsequently, a latitudinal incision was made on the ventral surface of the vein. A
polyurethane catheter was inserted into the vein and adjusted such that the final position of the
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catheter was at a level near, but not obstructing the right atrium. Once the catheter positioning
was complete and catheter patency verified, braided nylon sutures were placed proximal and
distal to the catheter cuff to secure the catheter to the vessel and these ties were used to anchor
the catheter to the surrounding fascia.
Subsequently, the subject was placed ventral side down on the surgical surface and one
longitudinal incision of 20 mm in length was made 10 mm right lateral to the mid-scapular point.
A second longitudinal incision of 3 mm in length was made at the mid-scapular point and the
cannula pedestal was inserted subcutaneously through the dorsal incision of 20 mm in length and
the upper post exposed through the dorsal incision of 3 mm in length. After, the distal end of the
catheter was passed subcutaneously from the ventral incision to the dorsal incision and secured
to the cannula pedestal and catheter patency verified again with sterile saline. Subsequently, all
incisions were closed with Michel wound clips. Catheter maintenance included a daily flush with
a sterile solution of 20 mg/kg amoxicillin, 10 mg/kg sublactam, 250 units/ml of heparin sodium in
a solution of 75 percent saline, 25 percent glycerol by volume. Catheter patency was verified at
periodic intervals with an intravenous administration of 7.5 mg/kg ketamine solution and confirmed
by the presence immediate onset sedation.
3.4 SELF-ADMINISTRATION PROCEDURE
On Day 5, subjects began self-administration testing conducted in standard operant
chambers housed within isolated and ventilated enclosures (Med Associates, Saint Albans, VT).
Each chamber was equipped with two response levers, a white stimulus light above each lever,
and a five-watt chamber light. Before each session, infusion tubing, protected by a stainless steel
spring tether (Plastics One, Roanoke, VA), was connected to the upper post of the implanted
cannula pedestal and the tether secured. Subsequently, infusions were delivered via a peristaltic
pump located outside of each enclosure. Control of the schedule parameters was performed with
MED-PC IV software and hardware (Med Associates, Saint Albans, VT). Subjects were
transported from the vivarium to the laboratory each day and allowed to acclimate for 15 to 30
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minutes prior to testing. In acquisition and maintenance sessions, each lever press on the
designated active lever (right lever), resulted in a 3-second infusion of 0.1-ml of 0.03 mg/kg
oxycodone solution and activation of the white stimulus light above the right lever. In this regard,
the white stimulus light paired with the delivery of oxycodone served as a conditioned cue.
Furthermore, the chamber light served as a discriminative stimulus signaling the availability of the
reinforcer. A 60-second timeout was imposed following each infusion during which the chamber
light was inactivated, and depression of the active lever was recorded but did not result in infusion
delivery. In these sessions, all lever-pressing behavior on the inactive lever (left lever) was
recorded, but had no programmed consequences. Subjects’ self-administration behavior met
acquisition criteria when the number of responses emitted was greater than or equal to 15 on the
active lever, and the number of responses on the active lever was greater than on the inactive
lever for three consecutive sessions. Once a subject met acquisition criteria, they continued
testing in self-administration sessions until they met stable maintenance criteria. Stable
performance was defined as a period of three consecutive days during which the daily mean
number of infusions did not differ from the mean number of infusions by more than 25 percent
and no trends of increasing or decreasing behavioral performance were evident.
Once subjects’ behavior met stable maintenance criteria, subjects were tested in
extinction sessions during which responses on the active lever had no programmed
consequences. In other words, responding did not result in the delivery of oxycodone or
presentation of oxycodone-associated cues, such as the white stimulus light. Subjects continued
testing in extinction sessions until self-administration behavior met extinction criteria. Extinction
criteria was defined as three consecutive days with response levels less than 50 percent of the
level of responses during stable maintenance performance.
Once subjects’ behavior met extinction criteria, subjects were tested in reinstatement
sessions for oxycodone prime-induced reinstatement (0.3, 1 mg/kg) or oxycodone-associated
cue-induced reinstatement. In prime-induced reinstatement sessions, conditions were identical to
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those conditions in the extinction sessions, however, 15 minutes prior to the session, a single
non-contingent injection of 0.3 or 1 mg/kg, subcutaneous (SC) oxycodone was delivered by the
experimenter. In cue-induced reinstatement sessions, conditions were similar to those conditions
in extinction sessions, however, depression of the designated active lever resulted in the
illumination of the white stimulus light above the designated active lever. Subjects’ testing for
reinstatement of lever-pressing behavior was counterbalanced for order, and subjects resumed
daily extinction sessions for at least three consecutive days and until performance met extinction
criteria between reinstatement tests.
Statistical analysis was performed on data collected including responses on the
designated active lever, responses on the designated inactive lever, and responses during the
timeout period. Significant main effects were determined with a Two-Way ANOVA with between
subject factors of fluid percussion condition (injured or non-injured) and schedule parameter
(maintenance, extinction, cue-induced reinstatement, or prime-induced reinstatement).
3.5 PHYSICAL DEPENDENCE PROCEDURE
3.5.1 PRECIPITATED WITHDRAWAL ASSAY
Two weeks prior to fluid percussion procedure on Day 0, subjects began training to emit
lever-pressing behavior for food pellet reinforcement under a FR5 schedule in daily 100-minute
sessions. Each session was comprised of five identical 20-minute trials. Each trial consisted of
three components presented in the following order: a 15-minute time-out period in which the
house-light was not illuminated and both left and right lever were absent; a 2-minute response
period in which the house-light was illuminated, the right lever was present and completion of a
FR5 on the right lever resulted in the presentation of a food pellet reinforcer; a 3-minute
observation period in which the house-light remained on, but both levers were absent. Once foodreinforced lever-pressing behavior was reliably established, subjects underwent the fluid
percussion injury procedure as described above, designated Day 0. On Day 6, dose effect curves
using cumulative doses of naltrexone (0, 1, 3, 10, 20 mg/kg, SC) were determined for suppression
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of food-reinforced lever-pressing behavior and production of other withdrawal signs. Each dose
was administered at the beginning of every 15-minute time-out period. In the 3-minute observation
period, precipitated withdrawal signs were scored as present or absent in three 1-minute intervals.
Opioid withdrawal signs measured included jumping, teeth chattering, salivation, face rubbing,
abdominal stretches, erection/genital grooming, wet dog shakes, ptosis, diarrhea, and lethargy.
On Day 6 at approximately 1800, following the determination of the baseline naltrexone
dose response curve, subjects were surgically implantated with sterile osmotic pumps (2ML2,
Alzet, Cupertino, CA). Subjects were anesthetized with 3 percent isoflurane vapor and one
longitudinal incision of approximately 20 mm in length was made on the back of each subject.
Blunt dissection of the fascia was performed to create sufficient space for accommodation of an
osmotic pump, which was then implanted subcutaneously and the surgical site closed with Michel
would clips. Subjects were divided approximately evenly into two groups: 1) a control group that
received osmotic pumps charged with a solution of sterile saline, and 2) a treatment group that
received osmotic pumps charged with a solution of oxycodone. A solution of oxycodone was
made to a concentration that allowed for the continuous and non-contingent delivery of 12
mg/kg/day (6x the ED80 value determined in an acute model of antinociception using a tail
immersion assay) at a rate of 5 microliters per hour for a total of 14 days. On Day 11, dose effect
curves using cumulative doses of naltrexone (0, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg, SC) were redetermined to assess changes in food-reinforced responding and withdrawal scores following
continuous treatment with saline or oxycodone.
Statistical analysis was performed on data collected including responses on the active
lever for food pellet reinforcer and mean composite withdrawal scores as assessed by the
experimenter. Significant main effects were determined with a Two-Way ANOVA with between
subject factors of fluid percussion condition (injured or non-injured) and osmotic pump treatment
condition (continuous oxycodone or continuous saline).
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3.5.2 SPONTANEOUS WITHDRAWAL ASSAY
On Day 12, subjects began training to emit lever-pressing behavior for food pellet
reinforcement under an FR5 schedule in three daily 30-minute, single-trial operant sessions. Each
session consisted of three components presented in the following order: a 15-minute time-out
period in which the house-light was not illuminated and both levers were absent; a 5-minute
response period in which the house-light was illuminated, the right lever was present, and
completion of a FR5 on the right lever resulted in the presentation of a food pellet reinforcer; and
a 10-minute observation period in which the house-light was on, but both levers were absent. On
Day 15 or 16, once food-reinforced behavior was reliably established, changes in food-reinforced
behavior and other withdrawal signs were assessed as previously described at approximately
0600, 1200, and 1800.
On Day 16 at approximately 2400, subjects were anesthetized with 4 percent isoflurane
vapor and one latitudinal incision of approximately 20 mm in length was made on the back of each
subject. Subsequently, the implanted osmotic pumps were removed and the surgical site closed
with Michel surgical clips. On Day 17, changes in food-reinforced responding and other withdrawal
signs were again assessed as previously described three times per day at approximately 0600,
1200, and 1800 for 60 hours.
Statistical analysis was performed on data collected including responses on the
designated active lever for food pellet reinforcer, and mean composite withdrawal scores as
assessed by the experimenter. Significant main effects were determined with a Three-Way
ANOVA with between subject factors of fluid percussion condition (injured or non-injured) and
osmotic pump treatment condition (continuous oxycodone or continuous saline), and time (18,
12, 6 hours prior to pump removal; 6, 12, 18, 30, 36, 42, 54, and 60 hours post pump removal).
3.5.2.1 LOCOMOTOR ACTIVITY ASSESSMENT
On Day 15 or 16, subjects were placed in an open field chamber (41cm X 41 cm X 20 cm)
equipped with 16 photobeam cells (ENV15, Med Associates, Saint Albans, VT) and allowed to
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ambulate freely for 30 minute, twice per day at approximately 0900 and 1500. On Day 17, subjects
were assessed for changes in locomotion during 30-minute sessions at approximately 0900 and
1500 and testing was repeated throughout the 60-hour spontaneous withdrawal assessment.
Distance traveled was determined based on photobeam breaks and was recorded and analyzed
using MedPC software (Med Associates, Saint Albans, VT).
Statistical analysis was performed on data collected including the total distance traveled
by each subject. Significant main effects were determined with a Three-Way ANOVA with
between subject factors of fluid percussion condition (injured or non-injured) and osmotic pump
treatment condition (continuous oxycodone or continuous saline), and time (18, 12, 6 hours prior
to pump removal; 6, 12, 18, 30, 36, 42, 54, and 60 hours post pump removal).
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CHAPTER 4: RESULTS
4.1 SELF-ADMINISTRATION PROCEDURE
For those subjects tested in the self-administration procedure, brain-injured subjects (n =
14; 606.73 ± 26.31), relative to non-injured subjects (n = 9; 288.22 ± 18.61), required significantly
more time to restore the righting reflex; t(22) = 8.586, p < 0.001. (FIGURE 1). In oxycodonereinforced sessions, brain-injured subjects (10.93 ± 0.78) showed no significant difference in the
mean number of sessions required to meet criteria for stable maintenance for lever-pressing
behavior relative to non-injured subjects (16.44 ± 3.14); t(9.010) = -1.705, p = 0.122 (FIGURE 2).
In non-reinforced extinction sessions, brain-injured subjects (10.67 ± 1.38) showed no significant
difference in the mean number of sessions required to meet criteria for extinction of lever-pressing
behavior relative to non-injured subjects (6.56 ± 1.14); t(22) = 2.059, p = 0.052 (FIGURE 3).
During stable maintenance of oxycodone-reinforced lever-pressing behavior, brain-injured
subjects (22.29 ± 1.50) emitted fewer oxycodone-reinforced lever presses than did non-injured
subjects (28.19 ± 8.66) [F (1, 155) = 20.102, P < 0.001] (FIGURE 4). During extinction of leverpressing behavior, there were no significant differences in active lever responding between braininjured subjects and non-injured subjects (FIGURE 4).
Once extinction criteria for lever-pressing behavior were met, all subjects were tested for
oxycodone-associated cue- and oxycodone prime-induced reinstatement (1 mg/kg, SC). A subset
of all subjects (n = 4, brain-injured; n = 6, non-injured), were also tested for oxycodone primeinduced reinstatement with 0.3 mg/kg, SC oxycodone administered prior to session start. In
reinstatement test sessions, brain-injured subjects lever-pressing behavior under oxycodoneassociated cue- and oxycodone prime-induced conditions showed no significant differences
relative to lever-pressing behavior during extinction sessions (FIGURE 4). However, non-injured
subjects’ lever-pressing behavior (18.22 ± 3.96) showed significant increases relative to leverpressing behavior in extinction sessions (10.30 ± 3.64) under oxycodone-associated cue-induced
reinstatement conditions, but not oxycodone prime-induced reinstatement conditions [F (1, 155)
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= 16.627, p < 0.001] (FIGURE 4). In these same tests, while brain-injured subjects showed no
significant differences in inactive lever responding from non-injured subjects during acquisition
sessions, brain-injured subjects emitted significantly fewer inactive lever presses during extinction
sessions (7.57 ± 1.55) than did the non-injured subjects (11.04 ± 2.65) [F (1, 155) = 5.261, p <
0.05] (FIGURE 5). However, both brain-injured subjects (1.93 ± 0.67) and non-injured subjects
(6.00 ± 2.74) showed decreases in inactive lever-pressing behavior during tests for oxycodone
prime-induced reinstatement (1 mg/kg, SC) relative to lever-pressing behavior during extinction
sessions [F (1, 155) = 3.744, p < 0.05] (FIGURE 5). During timeouts, there were no significant
differences in lever-pressing behavior between brain-injured subjects and non-injured subjects in
acquisition sessions, extinction sessions, or oxycodone prime-induced reinstatement sessions
(FIGURE 6). However, in test sessions for oxycodone-associated cue-induced reinstatement,
non-injured subjects showed an increase in lever-pressing behavior (52.67 ± 38.89) emitted
during timeouts which was significantly greater than their timeout responding in acquisition
sessions (37.93 ± 13.10) and extinction sessions (13.89 ± 4.85) [F (2, 155) = 9.308, p < 0.001]
(FIGURE 6).
In the subset of subjects tested for oxycodone prime-induced reinstatement (0.3 mg/kg,
SC), during oxycodone maintenance, brain-injured subjects’ lever-pressing behavior on the active
lever (20.83 ± 1.52) was significantly less than lever-pressing behavior of non-injured subjects on
the active lever (29.22 ± 3.36) [F (1, 64) = 3.744, p < 0.05] (FIGURE 7). However, during extinction
sessions, there were no significant differences in active lever responding between brain-injured
and non-injured subjects (FIGURE 7). In the reinstatement test sessions, brain-injured subjects
showed lever-pressing behavior on the active lever (9.25 ± 1.31) that was similar to lever-pressing
behavior during extinction sessions (7.75 ± 0.61), while non-injured subjects showed a significant
increase in lever-pressing behavior on the active lever (19.83 ± 6.32) relative to lever-pressing
behavior during extinction sessions (10.94 ± 1.21) [F (2, 64) = 36.48, p < 0.001] (FIGURE 7). In
these same tests, there was no significant difference in inactive lever-pressing behavior
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regardless of the schedule parameters or injury condition (FIGURE 8). During timeouts, braininjured subjects showed decreases in lever-pressing behavior relative to lever-pressing behavior
by non-injured subjects regardless of the schedule parameters, however this difference between
brain-injured subjects (15 ± 3.97) and non-injured subjects (34.94 ± 17.27) was only significant
during acquisition when oxycodone served to reinforce lever-pressing behavior [F (1, 64) = 4.860,
p < 0.05] (FIGURE 9).
4.2 PHYSICAL DEPENDENCE PROCEDURE
4.2.1 PRECIPITATED WITHDRAWAL ASSAY
For those subjects tested in the physical dependence procedure, brain-injured subjects (n
= 22; 693.00 ± 39.38), relative to non-injured subjects (n = 15; 279.13 ± 11.32) required
significantly more time to restore the righting reflex; t(24.367) = 10.100, p < 0.001 (FIGURE 10).
On Day 6, prior to pump implantation, the mean withdrawal scores observed in response to
challenge with naltrexone approached a value of zero for both brain-injured subjects and noninjured subjects with no significant differences observed across injury condition (FIGURE 11, 12,
13, 14). Similarly, there were no significant differences in mean withdrawal scores observed in
response to challenge with naltrexone between brain-injured and non-injured subjects after
treatment with continuously delivered oxycodone (FIGURE 11). However, the mean withdrawal
scores observed for subjects of both injury conditions were significantly elevated when challenged
with naltrexone after treatment with continuously delivered oxycodone relative to when challenged
with vehicle [F (4,65) = 23.300, p < 0.001] (FIGURES 11, 13, 14). In brain injured and non-injured
subjects treated with continuously delivered saline, there were no significant and biologically
relevant differences in mean withdrawal scores when challenged with naltrexone (FIGURE 12,
13, 14). Overall, there were no significant differences in naltrexone-generated mean withdrawal
scores between brain-injured subjects and non-injured subjects before or after treatment with
continuously delivered oxycodone (FIGURE 11) or saline (FIGURE 12).
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In subjects treated with continuously delivered oxycodone, there was a significant
difference in the mean number of food-reinforced lever presses before treatment for brain-injured
subjects and non-injured subjects when challenged with a dose of 3 mg/kg, SC naltrexone [F (1,
75) = 5.449, p < 0.05] and after treatment when challenged with the dose of 0.03 mg/kg, SC
naltrexone [F (1, 60) = 3.976, p < 0.05] (FIGURES 15, 17, 18). However, there was no significant
difference in the mean number food-reinforce lever presses between brain-injured and noninjured subjects when challenged with vehicle either before or after treatment with continuously
delivered oxycodone (FIGURE 15). Conversely, in subjects treated with continuously delivered
saline, brain-injured subjects and non-injured subjects showed significant baseline differences in
the mean number of lever presses both before [F (1, 80) = 24.530, p < 0.001] and after treatment
with continuously delivered oxycodone [F (1, 80) = 7.967, p < 0.05] with the non-injured subjects
showing greater lever-pressing behavior (FIGURE 16). Moreover, non-injured subjects
demonstrated greater lever-pressing behavior when challenged with naltrexone across all but the
highest dose tested after treatment with continuous saline (FIGURE 16). In both brain-injured
subjects [F (7, 87) = 8.379, p < 0.001] (FIGURE 17) and non-injured subjects [F (7, 53) = 13.726,
p < 0.001] (FIGURE 18) treated with continuously delivered oxycodone, a challenge with
naltrexone after treatment produced a dose-dependent (0.03, 0.1, 0.3 mg/kg, SC) attenuation in
the mean number of food-reinforced lever presses relative to the mean number of food-reinforced
lever presses after treatment with continuously delivered saline.
4.2.2 SPONTANEOUS WITHDRAWAL ASSAY
In the spontaneous withdrawal assay, there were no significant differences in mean
withdrawal scores across time between brain-injured subjects and non-injured subjects after
treatment with continuously delivered oxycodone (FIGURE 19) or saline (FIGURE 20). In braininjured subjects treated with continuous delivered oxycodone, mean withdrawal scores were
elevated at the 6 [F (1, 207) = 31.772, p < 0.001], 12 [F (1, 207) = 75.316, p < 0.001], 18 [F (1,
207) = 32.161, p <0.001], and 36 [F (1, 207) = 4.255, p <0.05] hour time points relative to brain36

injured subjects treated with continuously delivered saline (FIGURE 21). In non-injured subjects
treated with continuously delivered oxycodone, mean withdrawal scores were significantly
elevated at the 6 [F (1, 143) = 23.209, p < 0.001], 12 [F (1, 143) = 21.809, p < 0.001], 18 [F (1,
143) = 41.629, p < 0.001], 30 [F (1, 143) = 6.472), p < 0.05], 36 [F (1, 143) = 4.520, p < 0.05], and
42 [F (1, 143) = 9.591, p < 0.05] hour time points relative to non-injured subjects treated with
continuously delivered saline (FIGURE 22).
In subjects treated with continuously delivered oxycodone, there were no significant
differences in the mean number of food pellets earned between brain-injured or non-injured
subjects at any of the time points before or after pump removal (FIGURE 23). Similarly, in subjects
treated with continuously delivered saline, there were no significant and biologically relevant
differences in the mean number of food pellets earned between brain-injured and non-injured
subjects at any of the time points before or after pump removal (FIGURE 24). In brain-injured
subjects, those treated with continuously delivered oxycodone showed significant decreases in
the mean number of food pellets earned at the 6 [F (1, 209) = 4.283, p < 0.05)], 12 [F (1, 209) =
8.558, p < 0.01), and 18 [F (1, 209) = 3.852, p < 0.05] hour time points relative to those subjects
treated with continuous saline (FIGURE 25). In non-injured subjects, those treated with
continuously delivered oxycodone showed significant decreases in the mean number of food
pellets earned at all time points [F (10, 142) = 2.363, p < 0.05] (FIGURE 26).
4.2.2.1 LOCOMOTOR ACTIVITY ASSESSMENT
In the assessment of locomotor activity, brain-injured subjects that were treated with
continuously delivered oxycodone showed significant decreases in distance traveled at the 9 [F
(1, 198) = 17.431, p < 0.001], 33 [F (1, 198) = 7.543, p < 0.01], and 57 [F (1, 198) = 4.905, p <
0.05] hour time points, relative to brain-injured subjects that were treated with continuously
delivered saline (FIGURE 27). Subjects that were non-injured and treated with continuously
delivered oxycodone showed significant decreases in distance traveled at the 9 [F (1, 198) =
8.679, p < 0.01], 15 [F (1, 198) = 4.418, p < 0.05], and 33 [F (1, 198) = 10.466, p < 0.001] hour
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time points, relative to non-injured subjects that were treated with continuously delivered saline
(FIGURE 27). Overall, while subjects treated with continuously delivered saline traveled
significantly greater total distances relative to subjects treated with continuously delivered
oxycodone, there were no significant differences in total distance traveled within treatment groups
based on injury condition.
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FIGURE 1. Shown are the mean times required for the return of the righting reflex in seconds (±
standard error) for subjects tested in the self-administration procedure (n = 9, control; n = 14,
injured). * significantly different from control, p < 0.05.
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FIGURE 2. Shown are the mean number of sessions with oxycodone available (± standard
error) required by subjects to meet stable maintenance criteria (n = 9, control; n = 14, injured). *
significantly different from control at p < 0.05.
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FIGURE 3. Shown are the mean number of sessions (± standard error) without oxycodone
available required by subjects to meet extinction criteria (n = 9, control; n = 14, injured). *
significantly different from control at p < 0.05.
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FIGURE 4. Shown are the mean number of responses on the active lever (± standard error)
during FR1 oxycodone reinforced sessions (ACQ), following extinction training (EXT), during
cue- induced (CUE) and 1 mg/kg SC oxycodone prime-induced reinstatement (1PR) (n = 9,
control; n = 14, injured). * significantly different from control, p < 0.05. & significantly different
from extinction baseline within injury condition, p < 0.05.
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FIGURE 5. Shown are the mean number of responses on the inactive lever (± standard error)
during FR1 oxycodone reinforced sessions (ACQ), following extinction training (EXT), during
cue- induced (CUE) and 1 mg/kg SC oxycodone prime-induced reinstatement (1PR) (n = 9,
control; n = 14, injured). * significantly different from control injury, p < 0.05. & significantly
different from extinction baseline within injury condition, p < 0.05.
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FIGURE 6. Shown are the mean number of responses in the time out (± standard error) during
FR1 oxycodone reinforced sessions (ACQ), following extinction training (EXT), during cueinduced (CUE) and 1 mg/kg SC oxycodone prime-induced reinstatement (1PR) (n = 9, control; n
= 14, injured). * significantly different from control injury, p < 0.05. & significantly different from
extinction baseline within injury condition, p < 0.05.

44

R e in s t a t e m e n t - A c t iv e L e v e r

L e v e r P re s s e s ± S E M

35

CO NTRO L

30

&

25

IN J U R E D

*

20
15

*

10
5
0
ACQ

EXT

.3 P R

FIGURE 7. Shown are the mean number of responses on the active lever (± standard error)
during FR1 oxycodone reinforced sessions (ACQ), following extinction training (EXT), and 0.3
mg/kg SC oxycodone prime-induced reinstatement (.3PR) (n = 6, control; n = 4, injured). *
significantly different from control injury, p < 0.05. & significantly different from extinction
baseline within injury condition, p < 0.05.
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FIGURE 8. Shown are the mean number of responses on the inactive lever (± standard error)
during FR1 oxycodone reinforced sessions (ACQ), following extinction training (EXT), and 0.3
mg/kg SC oxycodone prime-induced reinstatement (.3PR) for sham controls (n = 6) and braininjured (n = 4) subjects. * significantly different from control injury, p < 0.05. & significantly
different from extinction baseline within injury condition, p < 0.05.
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FIGURE 9. Shown are the mean number of responses in the time out (± standard error) during
FR1 oxycodone reinforced sessions (ACQ), following extinction training (EXT), and 0.3 mg/kg
SC oxycodone prime-induced reinstatement (.3PR) for sham controls (n = 6) and brain-injured
(n = 4) subjects. * significantly different from control injury, p < 0.05. & significantly different from
extinction baseline within injury condition, p < 0.05.
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FIGURE 10. Shown are the mean times required for the return of the righting reflex righting in
seconds (± standard error) for subjects tested in the physical dependence procedure (n = 15,
control; n = 22, injured). * significantly different from control, p < 0.05.
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FIGURE 11. Shown are the mean withdrawal scores (± standard error) during baseline (PRE
dosing curves) and precipitated withdrawal sessions (POST dosing curves) induced by 0.03,
0.1, 0.3, 1, 3, 10, and 20 mg/kg SC naltrexone for sham control (n = 7) and brain-injured
subjects (n = 11) continuously delivered oxycodone 12 mg/kg/day for 5 days.
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FIGURE 12. Shown are the mean withdrawal scores (± standard error) during baseline (PRE
dosing curves) and precipitated withdrawal sessions (POST dosing curves) induced by 1, 3, 10,
and 20 mg/kg SC naltrexone for sham control (n = 7) and brain-injured subjects (n = 11)
continuously delivered saline for 5 days. * significantly different from injury control, p < 0.05.
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FIGURE 13. Shown are the mean withdrawal scores (± standard error) during baseline (PRE
dosing curves) and precipitated withdrawal sessions (POST dosing curves) induced by 0.03,
0.1, 0.3, 1, 3, 10, and 20 mg/kg SC naltrexone for brain-injured subjects continuously delivered
saline (n = 11) or oxycodone 12 mg/kg/day (n = 11) for 5 days. * significantly different from
vehicle p < 0.05.
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FIGURE 14. Shown are the mean withdrawal scores (± standard error) during baseline (PRE
dosing curves) and precipitated withdrawal sessions (POST dosing curves) induced by 0.03,
0.1, 0.3, 1, 3, 10, and 20 mg/kg SC naltrexone for sham control subjects continuously delivered
saline (n = 7) or oxycodone 12 mg/kg/day (n = 7) for 5 days. *significantly different from vehicle
p < 0.05.
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FIGURE 15. Shown are the mean number of food-reinforced lever presses emitted (± standard
error) during baseline (PRE dosing curves) and precipitated withdrawal sessions (POST dosing
curves) induced by 0.03, 0.1, 0.3, 1, 3, 10, and 20 mg/kg SC naltrexone for sham control (n = 7)
and brain-injured (n = 11) subjects continuously delivered oxycodone 12 mg/kg/day for 5 days. *
significantly different from injury control post-treatment. p < 0.05; & significantly different from
injury control pre-treatment, p < 0.05.
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FIGURE 16. Shown are the mean number of food-reinforced lever presses emitted (± standard
error) during baseline (PRE dosing curves) and precipitated withdrawal sessions (POST dosing
curves) induced by 1, 3, 10, and 20 mg/kg SC naltrexone for sham control (n = 7) and braininjured (n = 11) subjects continuously delivered saline for 5 days. * significantly different from
injury control post-treatment. p < 0.05; & significantly different from injury control pre-treatment,
p < 0.05.
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FIGURE 17. Shown are the mean number of food-reinforced lever presses emitted (± standard
error) during baseline (PRE dosing curves) and precipitated withdrawal sessions (POST dosing
curves) induced by 0.03, 0.1, 0.3, 1, 3, 10, and 20 mg/kg SC naltrexone both pre- and posttreatement for brain-injured subjects continuously delivered saline (n = 11) or oxycodone 12
mg/kg/day (n = 11) for 5 days. * significantly different from vehicle p < 0.05.
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FIGURE 18. Shown are the mean number of food-reinforced lever presses emitted (± standard
error) during baseline (PRE dosing curves) and precipitated withdrawal sessions (POST dosing
curves) induced by 0.03, 0.1, 0.3, 1, 3, 10, and 20 mg/kg SC naltrexone both pre- and posttreatement for sham control subjects continuously delivered saline (n = 7) or oxycodone 12
mg/kg/day (n = 7) for 5 days. * significantly different from vehicle p < 0.05.
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FIGURE 19. Shown are the mean withdrawal scores (± standard error) across time both preand post-pump removal for sham control (n = 8) and brain-injured (n = 10) subjects continuously
delivered oxycodone 12 mg/kg/day for 10 days.
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FIGURE 20. Shown are the mean withdrawal scores (± standard error) across time both preand post-pump removal for sham control (n = 7) and brain-injured (n = 11) subjects continuously
delivered saline for 10 days.
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FIGURE 21. Shown are the mean withdrawal scores (± standard error) across time both preand post-pump removal for sham control and brain-injured subjects continuously delivered
saline (n = 11) or oxycodone 12 mg/kg/day (n = 10) for 10 days. * significantly different from
control p < 0.05.
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FIGURE 22. Shown are the mean withdrawal scores (± standard error) across time both preand post-pump removal for sham control subjects continuously delivered saline (n = 7) or
oxycodone 12 mg/kg/day (n = 8) for 10 days. * significantly different from control p < 0.05.
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FIGURE 23. Shown are the mean number of food pellets earned (± standard error) across time
both pre- and post-pump removal for sham control (n = 8) and brain-injured (n = 10) subjects
continuously delivered oxycodone 12 mg/kg/day for 10 days.
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FIGURE 24. Shown are the mean number of food pellets earned (± standard error) from
reinforced lever presses across time both pre- and post-pump removal for both sham control (n
= 7) and brain injured (n = 11) subjects continuously delivered saline for 10 days. * significantly
different from control p < 0.05.
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FIGURE 25. Shown are the mean number of food pellets earned (± standard error) from
reinforced lever presses across time both pre- and post-pump removal for brain-injured subjects
continuously delivered saline (n = 11) or oxycodone 12 mg/kg/day (n = 10) for 10 days. *
significantly different from control p < 0.05.
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FIGURE 26. Shown are the mean number of food pellets earned (± standard error) from
reinforced lever presses across time both pre- and post-pump removal for sham control subjects
continuously delivered saline (n = 7) or oxycodone 12 mg/kg/day (n = 8) for 10 days. *
significantly different from control p < 0.05.
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FIGURE 27. Shown is the mean distance traveled (± standard error) in the open field across
time post-pump removal expressed as a percent control of the pre-pump removal baseline both
sham control and brain-injured subjects continuously delivered saline or oxycodone 12
mg/kg/day for 10 days. SHAM SAL (n = 14); SHAM OXY (n = 8); INJURED SAL (n = 12);
INJURED OXY (n = 11). * significant difference between INJURED SAL subjects and INJUIRED
OXY subjects, p < 0.05; & significant different between SHAM SAL subjects and SHAM OXY
subjects, p < 0.05.
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CHAPTER 5: DISCUSSION

In the first aim, we tested the hypothesis that moderate TBI increases the risk for relapse
to an opioid use disorder as measured by reinstatement of lever-pressing behavior following
extinction in an intravenous oxycodone self-administration procedure. Subjects sustaining a
moderate pressure pulse exhibited damage of central nervous tissue as indicated by elevated
latencies in the return of the righting reflex, a correlate of injury severity (FIGURE 1) [76–82]. Our
data, consistent with prior studies, show that oxycodone is an effective reinforcer of lever-pressing
behavior as indicated by preference for the oxycodone-reinforced lever relative to the nonreinforced lever (FIGURES 4, 7) [83–86]. In oxycodone-reinforced sessions, brain-injured
subjects emitted fewer active lever presses after meeting stable maintenance criteria than did
non-injured subjects (FIGURES 4, 7), but showed no significant differences in inactive lever
presses (FIGURES 5, 8). A possible explanation for the lower level of oxycodone selfadministration could be differences in the sensitivity to the reinforcing effects of oxycodone
following injury. A downward or leftward shift in the oxycodone dose-effect curve, a potency shift,
may reflect an increase in the sensitivity to the reinforcing effects of oxycodone [87–89]. It follows
that brain-injured subjects, relative to non-injured subjects, would require fewer infusions (read: a
lower cumulative intake) to achieve a comparable hedonic state or to reduce motivation for drugtaking. Moreover, changes in sensitivity to the reinforcing effects of a drug of abuse have been
correlated with relative risk for developing a substance use disorder [90]. Subjects that are more
sensitive to a drug, require less drug to achieve the desired effect, and subjects less sensitive to
the drug, administer more drug to achieve the desired effect [90]. Data suggest that subjects that
are exposed to more drug are more likely to develop a substance use disorder [90]. It follows,
then, that brain-injured subjects may be less likely develop an opioid use disorder. However,
further testing must be completed with additional doses of oxycodone and additional schedule
parameters to validate this hypothesis.
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In non-reinforced extinction tests, brain-injured subjects, relative to non-injured subjects
showed a trend to require a greater mean number of sessions to meet extinction criteria for leverpressing behavior (FIGURE 3). In these tests, all subjects met extinction criteria, but showed no
significant differences in mean lever presses during extinction sessions across injury condition
(FIGURE 4). In oxycodone prime-induced reinstatement tests (1 mg/kg, SC), brain-injured and
non-injured subjects showed decreases in lever-pressing behavior on the active lever, inactive
lever, and during timeouts relative to lever-pressing behavior during extinction tests (FIGURES
4–6). A decrease in lever-pressing behavior under these conditions, may represent a non-specific
depression of behavior due to the sedative effects of oxycodone [91]. When tested for oxycodone
prime-induced reinstatement at a lower dose (0.3 mg/kg, SC), non-injured subjects showed
significant increases in lever-pressing behavior relative to lever-pressing behavior during
extinction sessions (FIGURE 7). Our results, consistent with prior studies, suggest that oxycodone
priming injection is sufficient to reinstate previously extinguished lever-pressing behavior [37,40].
However, brain-injured subjects still failed reinstate to lever-pressing behavior under these
conditions (FIGURES 4, 7).
In tests for oxycodone-associated cue-induced reinstatement, non-injured subjects
showed significant increases in lever-pressing behavior relative to lever-pressing during extinction
sessions (FIGURE 4). Our results, consistent with prior studies, suggest that exposure to
oxycodone-associated cues following extinction are sufficient to reinstate lever-pressing behavior
[38,40,92–95]. In these tests, however, brain-injured subjects, relative to non-injured subjects,
showed no changes in lever-pressing behavior on the previously reinforced lever relative to leverpressing behavior during extinction tests (FIGURE 4).
A histological profile of the fluid percussion injury is well-established and indicates that
neurocircuits which mediate reinstatement to opioid-associated cues and opioid priming injection
may be disrupted [96–101]. Since injured regions, such as the hippocampus, cortex, and corpus
callosum, are among the discrete structures involved in these known circuits, it is logical to
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conclude that the reinstatement of behavior following extinction would be affected. It is also
established that opioid-associated cue and opioid-prime induced reinstatement are blocked by
temporary, bilateral inactivation of the basolateral amygdala with tetrodotoxin [102]. While the
histological injury profile suggests that the basolateral amygdala does not sustain damage either
ipsilateral or contralateral to the site of injury [97] it is known that reciprocal projections between
the basolateral amygdala, hippocampus, and cortex exist suggesting that disruption of these
discrete structures, are of importance [57,58,103,104]. It follows, then, that injury to the
hippocampus and cortex, by proxy of the basolateral amygdala, may be sufficient to attenuate the
salience of both exteroceptive and interoceptive stimuli [57]. In future studies, assays sensitive to
changes in the hippocampus, such as a novel object recognition assay or a self-administration
procedure with a renewal design, may aid in confirming injury to discrete structures involved in
reinstatement pathways by presence of behavioral disruption [105–111].
In the second aim, we tested the hypothesis that moderate TBI increases physiological
dependence to oxycodone as measured by decreases in food-reinforced lever-pressing behavior
and increases in other withdrawal behaviors in both precipitated withdrawal and spontaneous
withdrawal. Subjects sustaining a moderate pressure pulse exhibited damage of central nervous
tissue as indicated by elevated latencies in the return of the righting reflex, a correlate of injury
severity (FIGURES 10) [76–82]. In physiological dependence tests, brain-injured subjects,
relative to non-injured subjects showed no meaningful differences in experimenter assessed
withdrawal scores or food-reinforced lever-pressing behavior after treatment with continuous
oxycodone (FIGURES 11, 15). Our results, however, consistent with the results of other studies,
showed that continuous, non-contingent delivery of oxycodone leads to the development of
physical dependence for both brain-injured and non-injured subjects as evidenced by increases
in withdrawal scores (FIGURE 13, 14) and decreases in food-reinforced lever-pressing behavior
(FIGURE 17, 18) [71–75]. The consistent level of withdrawal across injury condition does not
support a change in the sensitivity to the effects of oxycodone as suggested by levels of
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oxycodone self-administration in the reinstatement study. An increase in the sensitivity to
oxycodone would be marked by upward and leftward shifts in the naltrexone dose-effects curves
for withdrawal scores, and downward and leftward shifts in the curves for food-reinforced leverpressing behavior. However, no meaningful differences in withdrawal scores or food-reinforced
lever-pressing behavior were observed in tests for precipitated withdrawal or spontaneous
withdrawal in subjects delivered continuous oxycodone.
In tests for food-reinforced lever-pressing behavior for subjects treated with continuous
saline, there were significant differences in baseline behavior which complicated the interpretation
of results. It is possible that this is due to failure to eliminate bias by counterbalancing subjects
with high baseline lever pressing behavior and low baseline lever pressing behavior across
treatment groups. However, expression of these data as a percent of vehicle control behavior
(data not shown) revealed no significant differences in food-reinforced lever pressing behavior
across the injury condition, except at the highest naltrexone dose tested. Moreover, there were
no differences in the mean composite withdrawal scores between brain-injured and non-injured
subjects, the primary comparison of interest.
These results indicate that there are no differences in the somatic signs of withdrawal, a
correlate for the development of physical dependence, between brain-injured subjects and noninjured subjects. Somatic signs of withdrawal may be mediated by the bed nucleus of the stria
terminalis, central nucleus of the amygdala, and hypothalamus [57,58,103]. Since the injury profile
does not indicate damage to either neuroanatomical pathways or discrete structures implicated
in the production of somatic signs of withdrawal, it follows that differences between brain-injured
subjects and non-injured subjects would not be expected. Other anatomical substrates mediating
expression of aversive opioid withdrawal behaviors include the ventral noradrenergic bundle, a
major source of noradrenergic projections to the bed nucleus of the stria terminalis [112] are not
believed to be disrupted as a result of the lateral fluid percussion injury [113,114]. Collectively,

69

these data may suggest that physical dependence and withdrawal does not contribute to an
increase in opioid use disorders in TBI patients.
Overall, the results of this study add to the collective knowledge of our understanding of
the relationship between brain injury and substance abuse through preclinical models of relapse
and physical dependence. Our relevant findings are summarized by several principal points. One,
that brain-injured subjects did not reinstate lever-pressing behavior under oxycodone-associated
cue or oxycodone prime-induced conditions, suggesting that brain-injured patients, with no
significant pre-morbid history, are at lesser risk of relapse to opioid abuse. Two, that brain-injured
subjects were not significantly different from non-injured subjects with regards to their mean
withdrawal scores or food-reinforced lever-pressing behavior, suggesting that the characteristic
withdrawal syndrome in opioid-dependent patients does not contribute to continued substance
use to greater degree in brain-injured patients versus non-injured patients. Contrary to the
epidemiological data about the relationship between brain injury and substance abuse, these
results suggest that brain injury appears to have no impact on oxycodone’s effects and may
actually decrease the motivation to take drug as well as the risk of relapse.
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